A landscape of driver mutations in melanoma

Cited by (1,006)

Items 501–600 of 1,006

1. Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy
   Duojiao Wu, Diane C. Wang, Yunfeng Cheng, Mengjia Qian, Miaomiao Zhang, Qi Shen, Xiangdong Wang · 2016 · Seminars in Cancer Biology
2. The protective role of DOT1L in UV-induced melanomagenesis
   Bo Zhu, Shuyang Chen, Hongshen Wang, Chengqian Yin, Changpeng Han, Cong Peng, Zhaoqian Liu, Lixin Wan, Xiaoyang Zhang, Jie Zhang et al. · 2018 · Nature Communications
3. Emerging insights into resistance to BRAF inhibitors in melanoma
   Amanda Dawn Bucheit, Michael A. Davies · 2013 · Biochemical Pharmacology
4. Translating Genomics for Precision Cancer Medicine
   Sameek Roychowdhury, Arul M. Chinnaiyan · 2014 · Annual Review of Genomics and Human Genetics
5. Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects
   Klaus Griewank, Richard A. Scolyer, John F. Thompson, Keith T. Flaherty, Dirk Schadendorf, Rajmohan Murali · 2014 · JNCI Journal of the National Cancer Institute
6. Towards Personalized Medicine in Melanoma: Implementation of a Clinical Next-Generation Sequencing Panel
   Blanca de Unamuno Bustos, Rosa Murria Estal, Gema Pérez-Simó, Inmaculada de Juan Jiménez, Begoña Escutia Muñoz, Mercedes Rodríguez Serna, Víctor Alegre de Miquel, Margarita Llavador Ros, Rosa Ballester Sánchez, Eduardo Nagore et al. · 2017 · Scientific Reports
7. Fibroblast Growth Factor Receptor Signaling in Skin Cancers
   Małgorzata Czyż · 2019 · Cells
8. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma
   Anne Fröhlich, Sophia Loick, Emma Bawden, Simon Fietz, Jörn Dietrich, Eric Diekmann, Gonzalo Saavedra, Holger Fröhlich, Dennis Niebel, Judith D. Sirokay et al. · 2020 · EBioMedicine
9. Melanogenesis and the Targeted Therapy of Melanoma
   Cang Li, Le Kuai, Rutao Cui, Xiao Miao · 2022 · Biomolecules
10. Indole-3-carbinol (I3C) analogues are potent small molecule inhibitors of NEDD4-1 ubiquitin ligase activity that disrupt proliferation of human melanoma cells
    Jeanne G. Quirit, Sergey N. Lavrenov, Kevin M. Poindexter, Janice H. Xu, Christine K. Kyauk, Kathleen A. Durkin, Ida Aronchik, Thomas M. Tomasiak, Yaroslav A. Solomatin, MARIA N. PREOBRAZHENSKAYA et al. · 2016 · Biochemical Pharmacology
11. ARID2 modulates DNA damage response in human hepatocellular carcinoma cells
    Atsushi Oba, Shu Shimada, Yoshimitsu Akiyama, Taketo Nishikawaji, Kaoru Mogushi, Hiromitsu Ito, Satoshi Matsumura, Arihiro Aihara, Yusuke Mitsunori, Daisuke Ban et al. · 2017 · Journal of Hepatology
12. DNA Mutations May Not Be the Cause of Cancer
    Adouda Adjiri · 2017 · Oncology and Therapy
13. Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice
    Inês Pires da Silva, Georgina Venetia Long · 2017 · Current Opinion in Oncology
14. Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF -Mutant Melanoma
    Inês Pires da Silva, Kevin Y. X. Wang, James S. Wilmott, Jeff Holst, Matteo Salvatore Carlino, John Park, Camelia Y. J. Quek, Matthew J. Wongchenko, Yibing Yan, Graham J. Mann et al. · 2019 · Clinical Cancer Research
15. Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis
    Shinichiro Kato, Qing Yu Weng, Megan L. Insco, Kevin Y. Chen, Sathya Muralidhar, Joanna Poźniak, Joey Mark S. Diaz, Yotam Drier, Nathalie T. Nguyen, Jennifer A. Lo et al. · 2020 · Cancer Discovery
16. Dysregulated FGF signalling in neoplastic disorders
    Yasmine Tanner, Richard Philip Grose · 2015 · Seminars in Cell and Developmental Biology
17. In vitro models of tumor vessels and matrix: Engineering approaches to investigate transport limitations and drug delivery in cancer
    Bo Ri Seo, Peter F. DelNero, Claudia Fischbach · 2013 · Advanced Drug Delivery Reviews
18. Aberrant GLI1 Activation in DNA Damage Response, Carcinogenesis and Chemoresistance
    Komaraiah Palle, Chinnadurai Mani, Kaushlendra K. Tripathi, Mohammad Athar · 2015 · Cancers
19. The landscape of fusion transcripts in spitzoid melanoma and biologically indeterminate spitzoid tumors by RNA sequencing
    Gang Wu, Raymond L. Barnhill, Seungjae Lee, Yongjin Li, Ying Shao, John B. Easton, James Dalton, Jinghui Zhang, Alberto S. Pappo, Armita Bahrami · 2016 · Modern Pathology
20. The Antiproliferative Response of Indole-3-Carbinol in Human Melanoma Cells Is Triggered by an Interaction with NEDD4-1 and Disruption of Wild-Type PTEN Degradation
    Ida Aronchik, Aishwarya Kundu, Jeanne G. Quirit, Gary L. Firestone · 2014 · Molecular Cancer Research
21. Public primary and secondary skin cancer prevention, perceptions and knowledge: an international cross‐sectional survey
    Sophie Seité, V. del Mármol, D. Moyal, Adam Friedman · 2017 · Journal of the European Academy of Dermatology and Venereology
22. The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function
    Lixin Wan, Ming Chen, Juxiang Cao, Xiangpeng Dai, Qing Yin, Jinfang Zhang, Su-Jung Song, Ying Lu, Jing Liu, Hiroyuki Inuzuka et al. · 2017 · Cancer Discovery
23. Cross‐species models of human melanoma
    Louise van der Weyden, E. Elizabeth Patton, Geoffrey A. Wood, Alastair K. Foote, Thomas Brenn, Mark Johan Arends, David J. Adams · 2015 · The Journal of Pathology
24. Polycomb repressive complex’s evolutionary conserved function: the role of EZH2 status and cellular background
    Koraljka Gall‐Tros̆elj, Renata Novak Kujundžić, Djurdjica Ugarkovic · 2016 · Clinical Epigenetics
25. Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma
    Grace P. Leung, Tianshu Feng, Frederic D. Sigoillot, Felipe Correa Geyer, Matthew D. Shirley, David A. Ruddy, Daniel P. Rakiec, Alyson K. Freeman, Jeffrey A. Engelman, Mariela Jaskelioff et al. · 2018 · Molecular Cancer Research
26. Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma
    Marie R. Webster, Mitchell E. Fane, Gretchen Marie Alicea, Subhasree Basu, Andrew V. Kossenkov, Gloria E. Marino, Stephen M. Douglass, Amanpreet Kaur, Brett Logan Ecker, Keerthana Gnanapradeepan et al. · 2019 · Molecular Cell
27. Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors
    Shilpa S. Dhar, Min Gyu Lee · 2021 · Oncotarget
28. Genomic Alterations in Langerhans Cell Histiocytosis
    Barrett J. Rollins · 2015 · Hematology/Oncology Clinics of North America
29. Protein Domain-Level Landscape of Cancer-Type-Specific Somatic Mutations
    Fan Yang, Evangelia Petsalaki, Thomas Rolland, DAVID EDWIN HILL, Marc Vidal, Frederick P. Roth · 2015 · PLoS Computational Biology
30. Transcriptional dissection of melanoma identifies a high-risk subtype underlying TP53 family genes and epigenome deregulation
    Brateil Badal, Alexander Solovyov, Serena Di Cecilia, Joseph Minhow Chan, Li‐Wei Chang, Ramiz Iqbal, Iraz T. Aydin, Geena Susan Rajan, Chen Chen, Franco Abbate et al. · 2017 · JCI Insight
31. Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts
    Dunnett-Kane, V., Burkitt-Wright, E., Blackhall, F.H., Malliri, A., Evans, D.G., Lindsay, C.R. · 2020 · Annals of Oncology
32. Sensitivity of plasma BRAFmutant and NRASmutant cell‐free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non‐RECIST disease progression
    Gregory A. Chang, Jyothirmayee S. Tadepalli, Yongzhao Shao, Yilong Zhang, Sarah Ann Weiss, Eric Michael Robinson, Cindy Spittle, Manohar R. Furtado, Dawne N. Shelton, George A. Karlin-Neumann et al. · 2015 · Molecular Oncology
33. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1
    S-H Chen, Xutong Gong, Youyan Zhang, Robert Daniel Van Horn, Tinggui Yin, L Huber, ThomasG. Burke, Jason R. Manro, Philip W. Iversen, Wenjuan Wu et al. · 2017 · Oncogene
34. Circulating tumor DNA‐based molecular residual disease detection for treatment monitoring in advanced melanoma patients
    Zeynep Eroglu, Shifra Krinshpun, Ekaterina V. Kalashnikova, Sumedha Sudhaman, Turkan Ozturk Topcu, Matt Nichols, Justin Martin, Katherine M. Bui, Charuta C. Palsuledesai, Meenakshi Malhotra et al. · 2023 · Cancer
35. Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin
    Gabriel Kenneth Griffin, Christopher A.G. Booth, Katsuhiro Togami, Sun Sook Chung, Daniel Ssozi, Julia A. Verga, Juliette Bouyssou, Yoke Seng Lee, Vignesh Shanmugam, Jason L. Hornick et al. · 2023 · Nature
36. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: Implications for melanoma staging and adjuvant therapy
    Andrew P. Barbour, Yue Tang, Nicola Armour, Ken Dutton‐Regester, Lutz Krause, Kelly A. Loffler, Duncan Lambie, Bryan Henry Burmeister, Janine M. Thomas, Bernard Mark Smithers et al. · 2014 · European Journal of Cancer
37. MEK targeting in N-RAS mutated metastatic melanoma
    Jaykumar Ranchodbhai Thumar, David Shahbazian, Saadia A. Aziz, Lucia B. Jilaveanu, Harriet M. Kluger · 2014 · Molecular Cancer
38. Molecular Pathways: Targeting NRAS in Melanoma and Acute Myelogenous Leukemia
    Douglas Buckner Johnson, Keiran S.M. Smalley, Jeffrey Alan Sosman · 2014 · Clinical Cancer Research
39. Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma
    Yongxia Zhu, Tinghong Ye, Xi Yong Yu, Qian Lei, Fangfang Yang, Yong Xia, Xuejiao Song, Li Liu, Hongxia Deng, Tiantao Gao et al. · 2016 · Scientific Reports
40. Mapping heterogeneity in patient-derived melanoma cultures by single-cell RNA-seq
    Tobias Gerber, Edith Willscher, Henry Loeffler‐Wirth, Lydia Hopp, Dirk Schadendorf, Manfred Schartl, Ulf Anderegg, J. Gray Camp, Barbara Treutlein, Hans Binder et al. · 2016 · Oncotarget
41. B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment
    Giulia Chiaruttini, Silvia Mele, James W. Opzoomer, Silvia Crescioli, Kristina M. Ilieva, Katie E. Lacy, Sophia N. Karagiannis · 2017 · OncoImmunology
42. Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications
    Robin John Lester Imperial, Omer M. Toor, Arif Hussain, Janakiraman Subramanian, Ashiq Masood · 2017 · Seminars in Cancer Biology
43. Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF V600E-Mutant Melanoma
    Zeynep Eroglu, Y. Ann Chen, Geoffrey Thomas Gibney, Jeffrey S. Weber, Ragini Reiney Kudchadkar, Nikhil I. Khushalani, Joseph Markowitz, Andrew Scott Brohl, Leticia F. Tetteh, Howida Ramadan et al. · 2018 · Clinical Cancer Research
44. Reemergence of neural crest stem cell-like states in melanoma during disease progression and treatment
    Diener, Johanna, Sommer, Lukas · 2021 · Stem Cells Translational Medicine
45. Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches
    for the Italian Melanoma Intergroup (IMI), Giuseppe Palmieri, Maria Colombino, Milena Casula, Antonella Manca, Mario Mandalà, Antonio Cossu · 2018 · Current Oncology Reports
46. Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling
    Ismael A. Vergara, Christopher Mintoff, Shahneen Kaur Sandhu, Lachlan McIntosh, Richard J. Young, Stephen Q. Wong, Andrew J. Colebatch, Daniel Cameron, Julia E Lai-Kwon, Rory S Wolfe et al. · 2021 · Nature Communications
47. Malignant Melanoma: An Overview, New Perspectives, and Vitamin D Signaling
    Radomir M. Slominski, Tae‐Kang Kim, Zorica Janjetović, Anna A. Brożyna, Ewa Podgórska, Katie Marie Dixon, Rebecca Sara Mason, Robert Charles Tuckey, Rahul Sharma, David K. Crossman et al. · 2024 · Cancers
48. Molecular and genetic diversity in the metastatic process of melanoma
    Katja Harbst, Martin Lauss, Helena Cirenajwis, Christof Winter, Jillian Howlin, Therese Törngren, Anders Kvist, Björn Nodin, Eleonor Olsson, Jari Häkkinen et al. · 2014 · The Journal of Pathology
49. Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma
    Victoria Marsh Durban, Marian M. Deuker, Marcus Bosenberg, Wayne Allen Phillips, Martin McMahon · 2013 · Journal of Clinical Investigation
50. Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies
    Kevin E. Fisher, Linsheng Zhang, Jason Wang, Geoffrey Hughes Smith, Scott Newman, Thomas M. Schneider, Rathi Narayana Pillai, Ragini Reiney Kudchadkar, Taofeek Kunle Owonikoko, Suresh S. Ramalingam et al. · 2016 · Journal of Molecular Diagnostics
51. The “ART” of Epigenetics in Melanoma: From histone “Alterations, to Resistance and Therapies”
    Thomas Strub, Robert Ballotti, Corine Bertolotto · 2020 · Theranostics
52. Mutations in ARID2 are associated with intellectual disabilities
    Linshan Shang, Megan T. Cho, Kyle Retterer, Leandra Folk, Jennifer B. Humberson, Luis O. Rohena, Alpa Sidhu, Sheila Saliganan, Alejandro D. Iglesias, Patrik Vitazka et al. · 2015 · Neurogenetics
53. A Single-Nucleotide Substitution Mutator Phenotype Revealed by Exome Sequencing of Human Colon Adenomas
    Sergey I. Nikolaev, Sotirios K. Sotiriou, Ioannis S. Pateras, Federico Andrea Santoni, Stavros Sougioultzis, Henrik Edgren, Henrikki Almusa, Daniel Robyr, Michel Guipponi, Janna Saarela et al. · 2012 · Cancer Research
54. Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients
    Matteo Salvatore Carlino, Carina Fung, Hamideh Shahheydari, Jason R. Todd, Suzanah C. Boyd, Mal Irvine, Adnan M. Nagrial, Richard A. Scolyer, Richard F. Kefford, Georgina Venetia Long et al. · 2014 · Clinical Cancer Research
55. Frequent DPH3 promoter mutations in skin cancers
    Evgeniya Denisova, Barbara Heidenreich, Eduardo Nagore, P. Sivaramakrishna Rachakonda, Md. Ismail Hosen, Ivana Akrap, Víctor Traves, Zaida García‐Casado, José Antonio López‐Guerrero, Celia Requena et al. · 2015 · Oncotarget
56. HUWE1 is a critical colonic tumour suppressor gene that prevents MYC signalling, DNA damage accumulation and tumour initiation
    Kevin Myant, Patrizia Cammareri, Michael C. Hodder, Jimi C. Wills, Alex von Kriegsheim, Balázs Győrffy, Mamun Rashid, Simona Polo, Elena Maspero, Lynsey S. Vaughan et al. · 2016 · EMBO Molecular Medicine
57. New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging
    Hailey E. Brighton, Steven P. Angus, Tao Bo, Jose Roques, Alicia C. Tagliatela, David B. Darr, Kübra Karagoz, Noah Sciaky, Michael L. Gatza, Norman E. Sharpless et al. · 2017 · Cancer Research
58. Cell cycle control as a promising target in melanoma
    Belinda Lee, Shahneen Kaur Sandhu, Grant A. McArthur · 2015 · Current Opinion in Oncology
59. FAT1 somatic mutations in head and neck carcinoma are associated with tumor progression and survival
    Shu‐Chun Lin, Li-Han Lin, Ssu-Yu Yu, Shou‐Yen Kao, Kuo‐Wei Chang, Hui-Wen Cheng, Chung‐Ji Liu · 2018 · Carcinogenesis
60. Depletion of TRRAP Induces p53‐Independent Senescence in Liver Cancer by Down‐Regulating Mitotic Genes
    Suet‐Yan Kwan, Ankur Sheel, Chun‐Qing Song, Xiao‐Ou Zhang, Tingting Jiang, Hien T. Dang, Yueying Cao, Deniz Mahmut Özata, Haiwei Mou, Hao Yin et al. · 2019 · Hepatology
61. Cardelino: computational integration of somatic clonal substructure and single-cell transcriptomes
    Davis James McCarthy, Raghd Rostom, Yuanhua Huang, Daniel J. Kunz, Petr Danecek, Marc Jan Bonder, Tzachi Hagai, Ruqian Lyu, Wenyi Wang, Daniel J. Gaffney et al. · 2020 · Nature Methods
62. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma
    Mayinuer Maitituoheti, Emily Zhi-Yun Keung, Ming Tang, Yan Liang, Hunain Alam, Guangchun Han, Anand Kamal Singh, Ayush T. Raman, Christopher J. Terranova, Sharmistha Sarkar et al. · 2020 · Cell Reports
63. Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling
    Christos Adamopoulos, Tamer A. Ahmed, Maxwell R. Tucker, Peter M.U. Ung, Min Xiao, Zoi Karoulia, Angelo Amabile, Xuewei Wu, Stuart A. Aaronson, Celina Ang et al. · 2021 · Cancer Discovery
64. Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong in vivo Antitumor Activity
    Lin Yang, Wenbin Tu, Liyue Huang, Bukeyan Miao, Atsunori Kaneshige, Wei Jiang, Lingying Leng, Meilin Wang, Bo Wen, Duxin Sun et al. · 2023 · Journal of Medicinal Chemistry
65. Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma
    Matteo Salvatore Carlino, Georgina Venetia Long, Richard F. Kefford, Helen Rizos · 2015 · Critical Reviews in Oncology/Hematology
66. Molecular Pathology of Skin Neoplasms of the Head and Neck
    Stefan Kraft, Scott R. Granter · 2014 · Archives of Pathology & Laboratory Medicine
67. Immunotherapy for skin cancer
    Kelly Garneski Paulson, Miranda C. Lahman, Aude G. Chapuis, Isaac Brownell · 2019 · International Immunology
68. Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis
    William P.D. Hendricks, Victoria Zismann, Karthigayini Sivaprakasam, Christophe Legendre, Kelsey Anne Poorman, Waibhav Tembe, Nieves Perdigones, Jeffrey Kiefer, Winnie S. Liang, Valerie J. DeLuca et al. · 2018 · PLoS Genetics
69. A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma
    Yangzi Tian, Weinan Guo · 2020 · Medical Science Monitor
70. Cutaneous Melanoma Classification: The Importance of High-Throughput Genomic Technologies
    Cristian Scatena, Daniela Murtas, Sara Tomei · 2021 · Frontiers in Oncology
71. Transforming acidic coiled-coil proteins (TACCs) in human cancer
    Geun‐Hyoung Ha, Jung‐Lye Kim, Eun-Kyoung Yim Breuer · 2013 · Cancer Letters
72. p53 regulates mesenchymal stem cell-mediated tumor suppression in a tumor microenvironment through immune modulation
    Yin Huang, Pengfei Yu, Wenzhao Li, Guangwen Ren, Anthony I. Roberts, Wei Cao, Xiaodan Zhang, Jiyan Su, Xun Chen, Qing Chen et al. · 2013 · Oncogene
73. Rac-Mediated Macropinocytosis of Extracellular Protein Promotes Glucose Independence in Non-Small Cell Lung Cancer
    Cindy Hodakoski, Benjamin David Hopkins, Guoan Zhang, Taojunfeng Su, Zhe Cheng, Roxanne Morris, Kyu Young Rhee, Marcus DaSilva Goncalves, Lewis C. Cantley · 2019 · Cancers
74. Sex disparities in melanoma outcomes: The role of biology
    Nosrati, Adi, Wei, Maria L. · 2014 · Archives of Biochemistry and Biophysics
75. Lineage-specific roles of the cytoplasmic polyadenylation factor CPEB4 in the regulation of melanoma drivers
    Eva Pérez‐Guijarro, Panagiotis Karras, Metehan Cifdaloz, Raúl Martínez-Herranz, Estela Cañón, Osvaldo Graña‐Castro, Celia Horcajada‐Reales, Direna Alonso‐Curbelo, Tonantzin G. Calvo, Gonzalo Goméz-López et al. · 2016 · Nature Communications
76. DNA methylation/hydroxymethylation in melanoma
    Siqi Fu, Haijing Wu, Huiming Zhang, Christine Guo Lian, Qianjin Lu · 2017 · Oncotarget
77. Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing
    Parvez M. Lokhandwala, Li‐Hui Tseng, Erika F. Rodriguez, Gang Zheng, Aparna Pallavajjalla, Christopher D. Gocke, James R. Eshleman, Ming‐Tseh Lin · 2019 · BMC Cancer
78. WNT and β-Catenin in Cancer: Genes and Therapy
    René Jackstadt, Michael C. Hodder, Owen James Sansom · 2019 · Annual Review of Cancer Biology
79. P53 in skin cancer: From a master player to a privileged target for prevention and therapy
    Joana B. Loureiro, Ana Margarida Abrantes, Paula A. Oliveira, Lucı́lia Saraiva · 2020 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
80. Oncogenic CDK13 mutations impede nuclear RNA surveillance
    Megan L. Insco, Brian J. Abraham, Sara J. Dubbury, Ines H. Kaltheuner, Sofia Dust, Constance Wu, Kevin Y. Chen, David Liu, Stanislav Bellaousov, Anna M. Cox et al. · 2023 · Science
81. H3K27 Methylation
    Jessica N. Nichol, Daphné Dupéré-Richer, Teresa Ezponda, Jonathan D. Licht, Wilson H. Miller · 2016 · Advances in cancer research
82. The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape
    Irene Vanni, Enrica T. Tanda, Francesco Spagnolo, Virginia Andreotti, William Bruno, Paola Ghiorzo · 2020 · Frontiers in Molecular Biosciences
83. In perspective: An update on telomere targeting in cancer
    Eric T. Sugarman, Gao Zhang, Jerry W. Shay · 2019 · Molecular Carcinogenesis
84. Non-Apoptotic Cell Death Signaling Pathways in Melanoma
    Mariusz L. Hartman · 2020 · International Journal of Molecular Sciences
85. Immunotherapy of Childhood Sarcomas
    Stephen S. Roberts, Alexander J. Chou, Nai‐Kong V. Cheung · 2015 · Frontiers in Oncology
86. Melanomas of unknown primary have a mutation profile consistent with cutaneous sun‐exposed melanoma
    Ken Dutton‐Regester, Hojabr Kakavand, Lauren G. Aoude, Mitchell S. Stark, Michael G. Gartside, Peter A. Johansson, Linda O’Connor, Cathy Lanagan, Varsha Tembe, Gulietta M. Pupo et al. · 2013 · Pigment Cell & Melanoma Research
87. Tumour mutation status and sites of metastasis in patients with cutaneous melanoma
    Nikki Rae Adler, Rory S Wolfe, John William Kelly, Andrew Mark Haydon, Grant A. McArthur, Catriona McLean, Victoria Mar · 2017 · British Journal of Cancer
88. Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment
    Wang, Manni, Liu, Yu, Cheng, Yuan, Wei, Yuquan, Wei, Xiawei · 2019 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
89. The evolution of the unstable cancer genome
    Rebecca A. Burrell, Charles Swanton · 2014 · Current Opinion in Genetics & Development
90. Conjunctival Melanoma: Current Treatments and Future Options
    Joseph M. Grimes, Nirav V. Shah, Faramarz H. Samie, Richard D. Carvajal, Brian P. Marr · 2020 · American Journal of Clinical Dermatology
91. MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis
    Varsha Tembe, Sarah‐Jane Schramm, Mitchell S. Stark, Ellis Patrick, Vivek Jayaswal, Yue Tang, Andrew P. Barbour, Nicholas K. Hayward, John F. Thompson, Richard A. Scolyer et al. · 2014 · Pigment Cell & Melanoma Research
92. Transposon mutagenesis identifies genetic drivers of BrafV600E melanoma
    Michael B. Mann, Michael A. Black, Devin J. Jones, Jerrold Michael Ward, Christopher Chin Kuan Yew, Justin Y. Newberg, Adam J. Dupuy, Alistair G. Rust, Marcus Bosenberg, Martin McMahon et al. · 2015 · Nature Genetics
93. P-Rex1 directly activates RhoG to regulate GPCR-driven Rac signalling and actin polarity in neutrophils
    George Damoulakis, Laure Gambardella, Kent L. Rossman, Campbell D. Lawson, Karen E. Anderson, Yoshinori Fukui, Heidi C. E. Welch, Channing J. Der, Len Stephens, Phillip T. Hawkins · 2014 · Journal of Cell Science
94. Developments in targeted therapy in melanoma
    Valerie C. Amann, Egle Ramelyte, S. Thurneysen, Rossella Pitocco, Nicoletta F. Jaberg-Bentele, Simone M. Goldinger, Reinhard Dummer, Joanna Mangana · 2016 · European Journal of Surgical Oncology
95. BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma
    Atul Kulkarni, Husam Al-hraishawi, Srilatha R. Simhadri, Kim Marie Hirshfield, Suzie Chen, Sharon R. Pine, Chandrika Jeyamohan, Levi O. Sokol, Siraj Mahamed Ali, Man Lung Teo et al. · 2017 · Clinical Cancer Research
96. Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy
    Verena Haselmann, Christoffer Gebhardt, Ingrid Brechtel, Angelika Duda, Claudia Czerwinski, Antje Sucker, Tim Holland‐Letz, Jochen Sven Utikal, Dirk Schadendorf, Michael Neumaier · 2018 · Clinical Chemistry
97. Quantitative conformational profiling of kinase inhibitors reveals origins of selectivity for Aurora kinase activation states
    Eric W. Lake, Joseph M. Muretta, Andrew R. Thompson, Damien M. Rasmussen, Abir Majumdar, Erik B. Faber, Emily F. Ruff, David Dale Thomas, Nicholas M. Levinson · 2018 · Proceedings of the National Academy of Sciences
98. RAC1 as a Therapeutic Target in Malignant Melanoma
    Alexa Christine Cannon, Cristina Uribe‐Alvarez, Jonathan Chernoff · 2020 · Trends in cancer
99. SMARCA family of genes
    Runjan Chetty, Stefano Serra · 2020 · Journal of Clinical Pathology
100. Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA
     S. Akumalla, Russell William Madison, Douglas I. Lin, Alexa Betzig Schrock, Evgeny Yakirevich, Mark Richard Rosenzweig, Arjun Vasant Balar, Garrett Michael Frampton, Claire I. Edgerly, Rachel Erlich et al. · 2020 · Oncology